<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00130923</url>
  </required_header>
  <id_info>
    <org_study_id>17359</org_study_id>
    <secondary_id>RIS-EMR-4032</secondary_id>
    <nct_id>NCT00130923</nct_id>
  </id_info>
  <brief_title>Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder</brief_title>
  <official_title>Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of oral risperidone (Risperdal) to
      risperidone long-acting (Consta) in reducing alcohol use in persons diagnosed with
      schizophrenia or schizoaffective disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comorbid alcohol/substance use disorder (SUD) in people with schizophrenia is a major
      concern, both in view of the high frequency of SUD among patients with schizophrenia and the
      difficulty in managing such patients. Though antipsychotic medications are effective in
      reducing symptoms and impairment in persons with schizophrenia, the typical antipsychotic
      agents are of limited value in controlling alcohol/substance use in these patients.
      Extrapyramidal, dysphoric side effects of conventional neuroleptics may actually promote the
      use of substances in an attempt to counteract these effects. In addition, medication
      non-compliance is common among patients with schizophrenia.

      Novel antipsychotics have altered treatment expectations and outcomes for patients with
      severe forms of schizophrenia. A growing number of studies have assessed the effects of oral
      risperidone in persons with dual disorders. Potential mechanisms of action by which
      risperidone and other atypical antipsychotics could decrease substance use include being less
      likely to cause extrapyramidal side effects than typical agents, improving negative symptoms
      and ameliorating a dysfunction of the brain reward system. Risperidone long-acting injectable
      medication addresses issues of noncompliance, while avoiding peak blood levels of oral
      preparations, thereby minimizing EPS and improving negative symptoms of schizophrenia.
      Risperidone may also facilitate dopamine neurotransmission in the prefrontal cortex and
      correct a hypothesized dysfunction of the brain reward system.

      This study is an open, randomized, controlled study to compare intramuscular long-acting
      risperidone to oral risperidone with blinded ratings to determine whether the long-acting
      form of risperidone has greater efficacy in reducing substance use. Patients with
      schizophrenia or schizoaffective disorder, age 18 to 65, who are taking any single oral
      antipsychotic medication except clozapine or risperidone long-acting may be enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Heavy Drinking Days Per Week</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other Substance Use as Assessed by the Timeline Followback Scale</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Symptoms, Global Functioning, Cognition, and Extrapyramidal System Effects</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Psychotic Disorders</condition>
  <condition>Substance Abuse</condition>
  <condition>Alcohol Abuse</condition>
  <arm_group>
    <arm_group_label>Risperidone Long Acting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risperidone Long Acting; aka Risperdal Consta; injectable form</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Risperidone; aka Risperdal; oral form</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone Long Acting</intervention_name>
    <description>Dose 25.00, 37.50 or 50.00 mg q two weeks</description>
    <arm_group_label>Risperidone Long Acting</arm_group_label>
    <other_name>Risperdal Consta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral risperidone</intervention_name>
    <description>0.50-6.00 mg oral risperidone daily</description>
    <arm_group_label>Oral Risperidone</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18-65

          -  Schizophrenia or schizoaffective disorder

          -  Meets the Structured Clinical Interview for DSM-IV (SCID) criteria for an alcohol use
             disorder

          -  Alcohol use on at least 5 days during the 4 weeks prior to randomization

          -  Patient is medically stable to start either form of risperidone.

        Exclusion Criteria:

          -  Current treatment with clozapine.

          -  Current treatment with injectable risperidone long-acting.

          -  Currently pregnant, planning to become pregnant, or unwilling to use an acceptable
             form of birth control.

          -  Change in medications (dose of current medication, discontinuation of medication, or
             new medication) in past 30 days.

          -  History of or current breast cancer.

          -  History of intolerance of or allergy to risperidone or risperidone long-acting.

          -  Currently residing in a residential program designed to treat substance use disorders.

          -  Current treatment with long-acting, injectable antipsychotic medication will require a
             review by the medication adjustment group before entering the client into the study.

          -  Past treatment with risperidone long-acting will require a review by the medication
             adjustment group before entering the client into the study.

          -  Treatment at baseline with a second antipsychotic medication will require a review by
             the medication adjustment group before entering the client into the study.

          -  Treatment at baseline with a psychotropic agent proposed to curtail substance use will
             require a review by the medication adjustment group before entering the client into
             the study.

          -  Patients who, in the opinion of the investigator, are judged unsuitable to participate
             in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan I. Green, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth Medical School, Dartmouth College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>JMH Mental Health Center, University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>School of Pharmacy, Univ. of Missouri Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Central Behavioral Health</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mental Health Center of Greater Manchester</name>
      <address>
        <city>Manchester</city>
        <state>New Hampshire</state>
        <zip>03101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Psychiatric Advancement</name>
      <address>
        <city>Nashua</city>
        <state>New Hampshire</state>
        <zip>03060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Carolina</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>White River Junction Veterans Admininistration Medical Center</name>
      <address>
        <city>White River Junction</city>
        <state>Vermont</state>
        <zip>05009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Albanese MJ, Khantzian EJ, Murphy SL, Green AI. Decreased substance use in chronically psychotic patients treated with clozapine. Am J Psychiatry. 1994 May;151(5):780-1.</citation>
    <PMID>8166327</PMID>
  </reference>
  <reference>
    <citation>Albanese M. Risperidone in substance abusers with bipolar disorder. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology. Sa Juan, PR, 2000.</citation>
  </reference>
  <reference>
    <citation>Akaike, H, Information theory and an extension of the maximum likelihood principle., in 2nd International Symposium on Information Theory and Control., EBN Petrovand &amp; C. Csaki, Editors. 1973, Akademia Kiado: Budapest, p. 267-281.</citation>
  </reference>
  <reference>
    <citation>Bartels SJ, Teague GB, Drake RE, Clark RE, Bush PW, Noordsy DL. Substance abuse in schizophrenia: service utilization and costs. J Nerv Ment Dis. 1993 Apr;181(4):227-32.</citation>
    <PMID>8473874</PMID>
  </reference>
  <reference>
    <citation>Birkett MA, Day SJ. Internal pilot studies for estimating sample size. Stat Med. 1994 Dec 15-30;13(23-24):2455-63.</citation>
    <PMID>7701146</PMID>
  </reference>
  <reference>
    <citation>Bowers MB Jr, Mazure CM, Nelson JC, Jatlow PI. Psychotogenic drug use and neuroleptic response. Schizophr Bull. 1990;16(1):81-5.</citation>
    <PMID>1970670</PMID>
  </reference>
  <reference>
    <citation>Buckley P, Thompson P, Way L, Meltzer HY. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am J Psychiatry. 1994 Mar;151(3):385-9.</citation>
    <PMID>8109646</PMID>
  </reference>
  <reference>
    <citation>Buckley P, Thompson PA, Way L, Meltzer HY. Substance abuse and clozapine treatment. J Clin Psychiatry. 1994 Sep;55 Suppl B:114-6.</citation>
    <PMID>7961553</PMID>
  </reference>
  <reference>
    <citation>Buckley PF. Novel antipsychotic medications and the treatment of comorbid substance abuse in schizophrenia. J Subst Abuse Treat. 1998 Mar-Apr;15(2):113-6.</citation>
    <PMID>9561949</PMID>
  </reference>
  <reference>
    <citation>Buckley PF. Substance abuse in schizophrenia: a review. J Clin Psychiatry. 1998;59 Suppl 3:26-30. Review.</citation>
    <PMID>9541335</PMID>
  </reference>
  <reference>
    <citation>Buckley PF, Miller A, Chiles JA, Sajatovic M. Implementing effectiveness research and improving care for schizophrenia in real-world settings. Am J Manag Care. 1999 Jun 25;5 Spec No:SP47-56.</citation>
    <PMID>10538860</PMID>
  </reference>
  <reference>
    <citation>Buckley P, McCarthy M, Chapman P, Richman C, Yamamoto B. Clozapine treatment of comorbid substance abuse in patients with schizophrenia. Schizophr Res 1999, 36:272.</citation>
  </reference>
  <reference>
    <citation>Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002 Oct;106(4):286-90.</citation>
    <PMID>12225495</PMID>
  </reference>
  <reference>
    <citation>Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 2000;26(2):441-9.</citation>
    <PMID>10885642</PMID>
  </reference>
  <reference>
    <citation>Frison L, Pocock SJ. Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med. 1992 Sep 30;11(13):1685-704.</citation>
    <PMID>1485053</PMID>
  </reference>
  <reference>
    <citation>Green AI, Zimmet SV, Strous RD, Schildkraut JJ. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry. 1999 Mar-Apr;6(6):287-96. Review.</citation>
    <PMID>10370435</PMID>
  </reference>
  <reference>
    <citation>Green AI, Salomon MS, Brenner MJ, Rawlins K. Treatment of schizophrenia and comorbid substance use disorder. Curr Drug Targets CNS Neurol Disord. 2002 Apr;1(2):129-39. Review.</citation>
    <PMID>12769622</PMID>
  </reference>
  <reference>
    <citation>Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res. 2003 Mar 1;60(1):81-5.</citation>
    <PMID>12505141</PMID>
  </reference>
  <reference>
    <citation>Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res. 2002 Apr 1;54(3):253-64.</citation>
    <PMID>11950550</PMID>
  </reference>
  <reference>
    <citation>Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry. 1985 Nov;142(11):1259-64. Review.</citation>
    <PMID>3904487</PMID>
  </reference>
  <reference>
    <citation>Khantzian EJ. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry. 1997 Jan-Feb;4(5):231-44. Review.</citation>
    <PMID>9385000</PMID>
  </reference>
  <reference>
    <citation>Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002 Oct;63(10):892-909. Review.</citation>
    <PMID>12416599</PMID>
  </reference>
  <reference>
    <citation>Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982 Dec;38(4):963-74.</citation>
    <PMID>7168798</PMID>
  </reference>
  <reference>
    <citation>Lee, ET. Statistical Methods for Survival Analysis. 1992, New York: John Wiley &amp; Sons.</citation>
  </reference>
  <reference>
    <citation>Newton TF, Ling W, Kalechstein AD, Uslaner J, Tervo K. Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Res. 2001 Jul 24;102(3):227-33.</citation>
    <PMID>11440773</PMID>
  </reference>
  <reference>
    <citation>Salyers MP, Mueser KT. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. Schizophr Res. 2001 Mar 1;48(1):109-23.</citation>
    <PMID>11278158</PMID>
  </reference>
  <reference>
    <citation>Siris SG. Pharmacological treatment of substance-abusing schizophrenic patients. Schizophr Bull. 1990;16(1):111-22. Review.</citation>
    <PMID>1970669</PMID>
  </reference>
  <reference>
    <citation>Smelson DA, Losonczy MF, Davis CW, Kaune M, Williams J, Ziedonis D. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry. 2002 Sep;47(7):671-5.</citation>
    <PMID>12355680</PMID>
  </reference>
  <reference>
    <citation>Tukey, JW. Exploratory Data Analysis. 1977, Reading, MA: Addison Wesley Publ. Co.</citation>
  </reference>
  <reference>
    <citation>Waternaux, C, Laird, N, Ware, J. Methods for the analysis of longitudinal data: Blood concentrations and cognitive development. J.Amer. Stat. Assoc. 1989: 84, p.33-41.</citation>
  </reference>
  <reference>
    <citation>Weiss RE, Lazaro CG. Residual plots for repeated measures. Stat Med. 1992 Jan 15;11(1):115-24.</citation>
    <PMID>1557567</PMID>
  </reference>
  <reference>
    <citation>Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AI. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol. 2000 Feb;20(1):94-8.</citation>
    <PMID>10653215</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2005</study_first_submitted>
  <study_first_submitted_qc>August 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2005</study_first_posted>
  <results_first_submitted>July 23, 2012</results_first_submitted>
  <results_first_submitted_qc>September 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 24, 2012</results_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Alan Green</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Risperidone</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Substance Use Disorder</keyword>
  <keyword>Alcohol Use Disorder</keyword>
  <keyword>Treatment</keyword>
  <keyword>Schizoaffective Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Risperidone Long Acting Injectable (LAI)</title>
          <description>Risperidone Long Acting Injectable (LAI), begun with 25 mg dose given intramuscularly(IM)every two weeks. The dose was titrated up to a target dose of 37.5 mg IM, with injections given every two weeks. The maximum dose of LAI risperidone was 50 mg every two weeks.</description>
        </group>
        <group group_id="P2">
          <title>Oral Risperidone Aka Risperal</title>
          <description>Oral Risperidone aka Risperdal. Participants who were randomized to take oral risperidone were titrated over two weeks up to a target dose of 4 mg per day. The maximum daily dose of oral risperidone was 6 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Risperidone Long Acting Injectable (LAI)</title>
          <description>Risperidone Long Acting Injectable (LAI), begun with 25 mg dose given intramuscularly(IM)every two weeks. The dose was titrated up to a target dose of 37.5 mg IM, with injections given every two weeks. The maximum dose of LAI risperidone was 50 mg every two weeks.</description>
        </group>
        <group group_id="B2">
          <title>Oral Risperidone Aka Risperal</title>
          <description>Oral Risperidone aka Risperdal. Participants who were randomized to take oral risperidone were titrated over two weeks up to a target dose of 4 mg per day. The maximum daily dose of oral risperidone was 6 mg.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="95"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.7" spread="10.1"/>
                    <measurement group_id="B2" value="41.7" spread="11.5"/>
                    <measurement group_id="B3" value="41.70" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Heavy Drinking Days Per Week</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Risperidone Long Acting Injectable (LAI)</title>
            <description>Risperidone Long Acting Injectable (LAI), begun with 25 mg dose given intramuscularly(IM)every two weeks. The dose was titrated up to a target dose of 37.5 mg IM, with injections given every two weeks. The maximum dose of LAI risperidone was 50 mg every two weeks.</description>
          </group>
          <group group_id="O2">
            <title>Oral Risperidone Aka Risperal</title>
            <description>Oral Risperidone aka Risperdal. Participants who were randomized to take oral risperidone were titrated over two weeks up to a target dose of 4 mg per day. The maximum daily dose of oral risperidone was 6 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Heavy Drinking Days Per Week</title>
          <units>Drinking days per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="2.0"/>
                    <measurement group_id="O2" value="1.9" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Substance Use as Assessed by the Timeline Followback Scale</title>
        <time_frame>6 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Symptoms, Global Functioning, Cognition, and Extrapyramidal System Effects</title>
        <time_frame>6 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Risperidone Long Acting Injectable (LAI)</title>
          <description>Risperidone Long Acting Injectable (LAI), begun with 25 mg dose given intramuscularly(IM)every two weeks. The dose was titrated up to a target dose of 37.5 mg IM, with injections given every two weeks. The maximum dose of LAI risperidone was 50 mg every two weeks.</description>
        </group>
        <group group_id="E2">
          <title>Oral Risperidone Aka Risperal</title>
          <description>Oral Risperidone aka Risperdal. Participants who were randomized to take oral risperidone were titrated over two weeks up to a target dose of 4 mg per day. The maximum daily dose of oral risperidone was 6 mg.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Injury, poisongin and procedural complications - Other, specify - Gunshot wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Injury, poisoning and procedural complications - Other, specify Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Injury, poisoning and procedural complications - Other, specify Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify Colon Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Delerium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Psychiatric Disorders - Other, specify - unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Psychiatric Disorders - Other, specify Substance Dependence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="8" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epitaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Disorder - Other, Hypersalivation</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Reactions</sub_title>
                <counts group_id="E1" events="15" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculo-Skeletal Connective Tissue Disorder-Other, Muscle Stiffness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Psychiatric Disorders - Other, Specify: Substance Dependence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile Disfunction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mary Brunette</name_or_title>
      <organization>Psychopharmacology Research Group</organization>
      <phone>603-271-5747</phone>
      <email>mary.f.brunette@hitchcock.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

